Company: ARTL
Filing Date: 2025-07-11
Form Type: S-1
Source: 0001640334-25-001190
Chunk: 30

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-07-11
Form: S-1
Chunk 30
---
 underwriting commissions or discounts under the Securities Act. If the Selling Securityholders are deemed to be underwriters, the Selling Securityholders may be subject to certain liabilities under statutes including, but not limited to, Section 11, 12 and 17 of the Securities Act and Section 10(b) and Rule 10b-5 under the Exchange Act.

The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Securityholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

We have agreed to keep this prospectus effective until all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.

In order to comply with the securities laws of some states, if applicable, the shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Securityholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Securityholders or any other person. We will make copies of this prospectus available to the Selling Securityholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

| 19 |

<div align='center'>PRINCIPALSTOCKHOLDERS</div>

The following table sets forth certain information with respect to the beneficial ownership of our Common Stock as of June 30, 2025 by:

| · | each person, or group of affiliated persons, who we know to beneficially own more than 5% of our Common Stock; |
| · | each of our named executive officers;                                                                          |
| · | each of our directors; and                                                                                     |
| · | all of our executive officers and directors as a group.                                                        |

The percentage beneficial ownership information